Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Plus Therapeutics ( (PSTV) ) has provided an update.
On June 3, 2025, Plus Therapeutics was notified by Nasdaq that it failed to meet the minimum stockholders’ equity requirement of $2.5 million, leading to a delist determination. However, after a hearing on July 15, 2025, the company was granted an extension to comply with the rule. By June 30, 2025, Plus Therapeutics reported stockholders’ equity of $3 million and continued to maintain compliance by selling over $2 million in common stock. The company also reported a market value of listed securities of at least $35 million for 20 consecutive business days as of August 13, 2025, meeting an alternative compliance threshold. Plus Therapeutics is awaiting Nasdaq’s confirmation of compliance with either the equity rule or the alternative market value requirement.
The most recent analyst rating on (PSTV) stock is a Buy with a $8.00 price target. To see the full list of analyst forecasts on Plus Therapeutics stock, see the PSTV Stock Forecast page.
Spark’s Take on PSTV Stock
According to Spark, TipRanks’ AI Analyst, PSTV is a Neutral.
Plus Therapeutics faces significant financial challenges with negative equity and ongoing losses. While there is some positive technical momentum, the valuation remains unattractive due to a negative P/E ratio and no dividend yield. Corporate events indicate strategic efforts to improve financial health but also highlight risks of potential delisting.
To see Spark’s full report on PSTV stock, click here.
More about Plus Therapeutics
Average Trading Volume: 31,449,070
Technical Sentiment Signal: Sell
Current Market Cap: $44.21M
Learn more about PSTV stock on TipRanks’ Stock Analysis page.